Find a Doctor

Carel B. Hoyng

Radboud University Medical Center

Bio


Carel Hoyng is in Nijmegen, Netherlands. They have been an author on 263 peer reviewed articles and participated in 2 clinical trials in the past 15 years.

Contact

Nijmegen, GE, NL

Latest Research


Latest Advance
Study
  • Condition: Diabetic Macular Edema
  • Journal: Ophthalmology. Retina
  • Treatment Used: Bevacizumab or Ranibizumab
  • Number of Patients: 170
  • Published —
This study compared the clinical outcome of using bevacizumab or ranibizumab to treat patients with diabetic macular edema.
Latest Advance
Study
  • Condition: Retinal Vein Occlusion (RVO)
  • Journal: Ophthalmology. Retina
  • Treatment Used: Bevacizumab vs. Ranibizumab
  • Number of Patients: 0
  • Published —
This study compared the effectiveness of intravitreal injections of bevacizumab to ranibizumab in the treatment of macular edema (swelling; ME) resulting from retinal vein occlusion (RVO).
Latest Advance
Study
  • Condition: Focal and Diffuse Chronic Central Serous Chorioretinopathy
  • Journal: American journal of ophthalmology
  • Treatment Used: Half-Dose Photodynamic Therapy or Subthreshold Micropulse Laser
  • Number of Patients: 156
  • Published —
This study compared the clinical outcome of using a half-dose photodynamic therapy or a subthreshold micropulse laser to treat patients with focal and diffuse chronic central serous chorioretinopathy.
Latest Advance
Study
  • Condition: Birdshot chorioretinopathy
  • Journal: Retina (Philadelphia, Pa.)
  • Treatment Used: Adalimumab
  • Number of Patients: 19
  • Published —
The study researched the safety and effectiveness of Adalimumab for birdshot chorioretinopathy.

Clinical Trials


Clinical Trial
  • Status: Recruiting
  • Participants: 40
  • Start Date: December 17, 2017
Natural History Study of CEP290-Related Retinal Degeneration

All Publications
View All


Publication
Conference
  • Sponsor: American Society of Human Genetics (ASHG)
  • Event Name: American Society of Human Genetics Annual Meeting 2020
  • Published —
Structural variants create new topological associated domains and ectopic retinal enhancer-gene contact in dominant retinitispigmentosa.

Contact

Nijmegen, GE, NL

Insurance

Contact them to find out if they accept your insurance plan.